Viability of Dugesia dorotocephala Planaria with the Senolytic Drug ARV-825
Abbie Wells, William H. Munroe
TL;DR
This study tests the effect of the drug ARV-825 on planaria and finds that higher concentrations reduce their survival.
Contribution
The study introduces planaria as a potential model organism for testing the senolytic drug ARV-825.
Findings
Planaria survival decreased from 91.7% at 1µM ARV-825 to 25% at 10µM.
ARV-825, a PROTAC targeting BRD4, affects planaria viability in a concentration-dependent manner.
Abstract
Planaria ( Dugesia dorotocephala ) are being utilized as a model system to test the effectiveness of ARV-825. ARV-825 belongs to the drug class proteolysis targeting chimeras (PROTACs), which targets and degrades the protein Bromodomain-containing protein 4 (BRD4) via the proteasome. To examine the impact of ARV-825 on the planaria, planaria viability was tested at different ARV-825 concentrations. This demonstrated a concentration-dependent reduction in viability, 91.7% survival with 1µM ARV-825 reduced to 25% survival in 10 µM ARV-825. This suggests ARV-825 has an effect on Dugesia dorotocephala , and indicates that this may be a suitable model organism for studying ARV-825.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCellular Mechanics and Interactions · Planarian Biology and Electrostimulation · Viral Infectious Diseases and Gene Expression in Insects